Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive acetazolamide with furosemide in critically ill ICU patients
ACTRN12625001184460Phase 2Not yet recruiting
- Sponsor
- Austin Health
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in critical illness, hypervolemia and chronic kidney disease (CKD) comparing Adjunctive acetazolamide with Furosemide only (2 arms). Primary endpoint: Mean difference in base excess over 48 hours. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
acetazolamidefurosemide
03
Conditions
critical illnesshypervolemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ACTRN12625001184460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001184460.